(Last updated 3/13/2017; last reviewed 3/13/2017)
An HIV regimen is a combination of HIV medicines used to treat HIV infection. HIV treatment (also called antiretroviral therapy or ART) begins with choosing an HIV regimen. People on ART take the HIV medicines in their HIV regimens every day. ART helps people with HIV live longer, healthier lives and reduces the risk of HIV transmission.
There are more than 25 HIV medicines approved by the U. S. Food and Drug Administration (FDA) to treat HIV infection. Some HIV medicines are available in combination (in other words, two or more different HIV medicines combined in one pill).
The U.S. Department of Health and Human Services (HHS) provides guidelines on the use of HIV medicines. In general, the guidelines recommend starting ART with a regimen that includes three HIV medicines from at least two different drug classes.
In general, a person's first HIV regimen includes two NRTIs plus an INSTI, an NNRTI, or a PI boosted with cobicistat (brand name: Tybost) or ritonavir (brand name: Norvir). Cobicistat or ritonavir increase (boost) the effectiveness of the PI.
Click here to see the AIDSinfo fact sheet that lists the FDA-approved HIV medicines by drug class.
The HHS guidelines on the use of HIV medicines in adults and adolescents recommend several regimens for people starting ART. The best regimen for a person depends on their individual needs.
Viral load is the amount of HIV in a person’s blood. A main goal of ART is to reduce a person’s viral load to an undetectable level. An undetectable viral load means that the level of HIV in the blood is too low to be detected by a viral load test.
Once effective ART is started, it usually takes 3 to 6 months for a person’s viral load to reach an undetectable level. Having an undetectable viral load doesn’t mean a person’s HIV is cured. But although there is still some HIV in the person’s body, an undetectable viral load shows that ART is working effectively. Effective ART helps people with HIV live longer, healthier lives and reduces the risk of HIV transmission.